Trial reportBMC ophthalmology2025
Impact of optical correction with ordinary spherocylindrical spectacle lenses versus defocus incorporated multiple segments (DIMS) spectacle lenses on ocular alignment and binocular visual function in teenagers with myopia.
Trial report in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Short-Term Residual Myopic Bias Measured by Open-Field Autorefraction After 10-Second Myopic Overcorrection in Young Myopic Adults.Vision (Basel, Switzerland) · 2026Article
- Binocular Visual Function in Children Wearing Single-Vision or Highly Aspherical Lenslet Spectacle Lenses Assessed with a Tablet-Based Dichoptic Platform.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo compare the effects of ordinary spherocylindrical spectacle lenses versus defocus incorporated multiple segments (DIMS) spectacle lenses on ocular alignment and binocular visual functions in teenagers with myopia over a 2-year period.
methods120 myopic teenagers aged 12–18 years were randomly allocated to wear either ordinary spherocylindrical single vision spectacle lenses (SV group, n = 60) or DIMS spectacle lenses (DIMS group, n = 60) for 2 years.
resultsAfter 2 years, the DIMS group exhibited significantly smaller exophoric shifts in ocular alignment compared to the SV group at distance (1.5 ± 2.2 vs. 3.4 ± 3.1 PD, p = 0.001) and near (3.7 ± 4.1 vs. 6.8 ± 5.4 PD, p < 0.001). The DIMS group also demonstrated better preserved stereoacuity [values log10-transformed for statistical analysis but presented here in arcsec for clinical interpretability] (32 ± 12 vs. 48 ± 20 arcsec, p < 0.001), near point of convergence (7.2 ± 2.3 vs. 9.5 ± 3.6 cm, p = 0.001), and fusional vergence ranges (positive: 24 ± 8 vs. 18 ± 7 PD, p = 0.002; negative: 14 ± 5 vs. 11 ± 4 PD, p = 0.01) than the SV group at 2 years. The mean myopia progression over 2 years was significantly slower in the DIMS group than the SV group (-0.72 ± 0.32 vs. -1.25 ± 0.45 D, p < 0.001), with less axial elongation (0.41 ± 0.18 vs. 0.65 ± 0.25 mm, p < 0.001). The proportions of participants with clinically significant changes in ocular alignment (≥ 10 PD exophoria), stereoacuity (≥ 0.3 log arcsec loss), and convergence (≥ 4 cm recession in near point of convergence) were significantly lower in the DIMS group compared to the SV group (all p < 0.05).
conclusionsIn myopic teenagers, DIMS spectacle lenses used for optical correction were associated with smaller changes in ocular alignment and binocular visual functions, and slowed myopia progression by 42% in terms of spherical equivalent refraction (SER). These results suggest that DIMS lenses may be effective in controlling both refractive progression and certain binocular function changes in adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.